Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase by Henderson, Sara R et al.
Structural and mechanistic analysis of ATPase inhibitors targeting
mycobacterial DNA gyrase
Sara R. Henderson1†, Clare E. M. Stevenson1, Brandon Malone1‡, Yelyzaveta Zholnerovych1, Lesley A. Mitchenall1,
Mark Pichowicz2§, David H. McGarry2¶, Ian R. Cooper2||, Cedric Charrier2#, Anne-Marie Salisbury2**,
David M. Lawson1 and Anthony Maxwell 1*
1Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK; 2Redx Pharma PLC, Mereside,
Alderley Park, Alderley Edge SK10 4TG, UK
*Corresponding author. E-mail: tony.maxwell@jic.ac.uk
†Present address: Norwich Medical School, University of East Anglia, Norwich NR4 7UQ, UK.
‡Present address: Laboratory of Molecular Biophysics, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
§Present address: Sygnature Discovery, The Discovery Building, Biocity, Pennyfoot Street, Nottingham NG1 1GR, UK.
¶Present address: Globachem Discovery Ltd, Mereside, Alderley Park SK10 4TG, UK.
||Present address: AMR Centre Ltd, Mereside, Alderley Park SK10 4TG, UK.
#Present address: IHMA Europe Sa`rl, Rte. de I’lle-au-Bois 1A, 1870 Monthey/VS, Switzerland.
**Present address: 5D Health Protection Group Ltd, William Henry Duncan Building, West Derby Street, Liverpool L7 8TX, UK.
Received 10 March 2020; returned 16 April 2020; revised 28 May 2020; accepted 30 May 2020
Objectives: To evaluate the efficacy of two novel compounds against mycobacteria and determine the molecu-
lar basis of their action on DNA gyrase using structural and mechanistic approaches.
Methods: Redx03863 and Redx04739 were tested in antibacterial assays, and also against their target, DNA
gyrase, using DNA supercoiling and ATPase assays. X-ray crystallography was used to determine the structure of
the gyrase B protein ATPase sub-domain from Mycobacterium smegmatis complexed with the aminocoumarin
drug novobiocin, and structures of the same domain from Mycobacterium thermoresistibile complexed with
novobiocin, and also with Redx03863.
Results: Both compounds, Redx03863 and Redx04739, were active against selected Gram-positive and
Gram-negative species, with Redx03863 being the more potent, and Redx04739 showing selectivity against
M. smegmatis. Both compounds were potent inhibitors of the supercoiling and ATPase reactions of DNA gyrase,
but did not appreciably affect the ATP-independent relaxation reaction. The structure of Redx03863 bound to
the gyrase B protein ATPase sub-domain from M. thermoresistibile shows that it binds at a site adjacent to
the ATP- and novobiocin-binding sites. We found that most of the mutations that we made in the Redx03863-
binding pocket, based on the structure, rendered gyrase inactive.
Conclusions: Redx03863 and Redx04739 inhibit gyrase by preventing the binding of ATP. The fact that the
Redx03863-binding pocket is distinct from that of novobiocin, coupled with the lack of activity of resistant
mutants, suggests that such compounds could have potential to be further exploited as antibiotics.
Introduction
Although TB, caused by the bacterium Mycobacterium tuberculosis,
is often thought of as a disease of the past, in recent years there
have been increasing rates of the disease. This is in part due to ris-
ing resistance to the current primary treatment regimen—directly
observed treatment, short-course (DOTS)—and decreasing effi-
cacy of the BCG vaccine (https://www.who.int/tb/publications/glo
bal_report/en/).1 To overcome this issue, there have been signifi-
cant efforts to develop new treatments, which have, for the most
part, been unsuccessful, the current first-line treatments having
been used for over 50 years. One strategy is to find new com-
pounds that exploit existing well-validated targets, such as DNA
gyrase, which is a member of the DNA topoisomerase family of
enzymes.2,3
DNA topoisomerases are enzymes that regulate the topology
of DNA in all cells.4 They are classified into two types, I and II, de-
pending on whether their reactions involve single (I)- or double
(II)-stranded breaks in DNA. Gyrase is a type II topoisomerase and
the only enzyme that can catalyse the introduction of negative
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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supercoils into DNA;3,5 it is composed of two subunits, GyrA and
GyrB, which form an A2B2 complex in the active enzyme. Gyrase is
an essential enzyme in bacteria and has been extensively studied
as a target for antibacterial agents;6 gyrase has been described as
an effective drug target for the development of new anti-TB
agents.2 Gyrase is the only type II topoisomerase in M. tuberculosis
and, in addition to supercoiling, carries out functions that would be
carried out by DNA topoisomerase IV (topo IV) in other bacteria,
such as decatenation.7,8
Several small-molecule antibiotics and bacterial toxins target
gyrase, the most prominent of which are the fluoroquinolones
(FQs).9,10 Indeed, these compounds (e.g. moxifloxacin) have
been utilized in TB therapy.11 FQs inhibit gyrase by stabilizing the
DNA-cleavage complex, a transient intermediate in the DNA super-
coiling cycle, which, in vivo, can lead to chromosome breaks and
cell death.9,10 Other compounds, such as the aminocoumarins
(e.g. novobiocin), inhibit gyrase through targeting the ATPase
domains of gyrase and topo IV, located in the N-terminal domain
of GyrB (and ParE), thus preventing supercoiling.3,12 Although ami-
nocoumarins have not enjoyed the same clinical success as FQs,
inhibition of the ATPase activity is a very effective way of inhibiting
the enzyme, and the existence of several crystal structures of this
region has enabled the development of a range of inhibitory
molecules.13,14
Previously, compounds with a pyrrolopyrimidine core have
been described as having broad-spectrum antibacterial activity
through targeting the ATPase domains of gyrase and topo IV with
high potency against Gram-positive bacteria and weaker activity
against Gram-negative bacteria.15,16 The introduction of a third
cyclic ring to the pyrrolopyrimidine core creates a tricyclic ring sys-
tem with improved antibacterial efficiency against Gram-positive
bacteria.17 The mechanism of action was determined to be due to
inhibition of the ATPase activity of GyrB and ParE (the equivalent
subunit of topo IV). Crystal structures of several of the compounds
in the series, bound to a variety of Gram-negative GyrB
and ParE subunits, have been solved by X-ray crystallography.15–17
The binding pocket inferred from crystallography shows that the
pyrrolopyrimidine-containing compounds bind in a similar pocket
to novobiocin in GyrB, but Arg136 (Escherichia coli numbering)
does not make direct contact with the compounds, as distinct
from novobiocin. More recently, these compounds have been fur-
ther developed to create the current series with increased specifi-
city against mycobacteria.18 Additionally, it has been shown that
these compounds inhibit the supercoiling and ATPase reactions of
M. tuberculosis gyrase without inhibiting human topoisomerase II,
and maintain activity against a panel of relevant M. tuberculosis
clinical isolates resistant to other commonly used drugs.18
In this paper we have extended this work using two
compounds (Figure 1) and show that they are effective inhibitors
of M. tuberculosis gyrase and inhibit the growth of Mycobacterium
smegmatis. In addition, we present crystal structures of the
GyrB N-terminal ATPase sub-domain from Mycobacterium
thermoresistibile bound to one of these compounds (Redx03863)
and also to novobiocin, demonstrating that this novel compound
class inhibits via a binding pocket and resistance mechanism
different from that of novobiocin. It is important to note that all
the residues that line the ATP pocket are conserved across
M. tuberculosis, M. smegmatis and M. thermoresistibile, i.e. the lat-
ter two are good models for the former in this context.
Materials and methods
Antibacterial testing
Antibacterial testing was performed for Acinetobacter baumannii
NCTC 13420, E. coli ATCC 25922, M. smegmatis ATCC 19420, Pseudomonas
aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 29213, using the
broth microdilution method under CLSI guidelines19 (Table 1). The agar di-
lution method was additionally performed for M. smegmatis under EUCAST
guidelines.20
Bacterial mutagenesis
Single colonies of M. smegmatis ATCC 19420 were grown for 48 h at 37C
with shaking in Middlebrook 7H9 broth supplemented with 10% (v/v) OADC,
0.2% (v/v) glycerol and 0.05% (v/v) Tween 80. Fifty microlitres of starter
culture was used to inoculate 10 mL agar plates containing 4% agar MIC of
Redx03863. Colonies were selected after 5 days of incubation at 37C and
Figure 1. Structures of Redx03863 and Redx04739.
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confirmed by testing broth MIC values. Cross-resistance was tested for a
panel of compounds, and the genomic DNA was extracted (EdgeBio
PurEluteTM Bacterial Genomic Kit, with bead beating lysis step). The DNA
gyrase genes were amplified using PCR, purified (Qiagen PCR clean-up kit)
and products sequenced (Eurofins Genomics) (Table S1, available as
Supplementary data at JAC Online).
Protein purification and crystallization
The M. smegmatis GyrB 22 kDa ATPase sub-domain was cloned, purified
and crystallized as described,21 resulting in a double loop-deletion mutant
of the 27 kDa N-terminal ATPase sub-domain. Crystals grown, using sitting-
drop vapour diffusion, with 17 mg/mL protein in the presence of 1 mM
novobiocin against 15% (w/v) PEG8000, 100 mM sodium acetate pH 5.6,
200 mM calcium acetate, were harvested in the precipitant supplemented
with 25% (v/v) ethylene glycol for cryoprotection.
The M. thermoresistibile GyrB 21 kDa ATPase sub-domain (residues
20–213) was cloned to be analogous to the M. smegmatis construct with
two potentially flexible loops (residues 103–123 and 214–244) removed.
Purification was performed under the same conditions as for the
M. smegmatis protein. Purified protein, at a concentration of 22 mg/mL,
was supplemented with 1 mM novobiocin or 0.24 mM Redx03863, before
crystallization by sitting-drop vapour diffusion against 100 mM zinc chlor-
ide, 100 mM ammonium acetate, 3.5%–5% (w/v) PEG6000, 3.5%–5% (w/v)
PEG8000, 3.5%–5% (w/v) PEG1000 and 100 mM Bis-Tris pH 7.0–7.3 with as-
sistance of seeding. Briefly, crystals containing novobiocin were harvested
after 7–10 days in 40–100lL of mother liquor, and vortexed vigorously for
4 min with three 1 mm glass beads in 1.5 mL Eppendorf tubes, and 0.1lL
was used to supplement future crystal trials with 0.2lL screen and 0.3lL
of protein solution. Crystals were harvested in precipitant supplemented
with 25% (v/v) ethylene glycol.
X-ray data collection and structure solution
Data collection was performed on beamlines I03 and I04-1 at Diamond
Light Source (Oxford, UK) with the crystals maintained at #173C using a
Cryojet cryocooler (Oxford Instruments). X-ray data were collected for
3600%0.1 images at a wavelength of 0.97 A˚ to a maximum resolution of
1.3 A˚ with a Pilatus3 6 M Hybrid Photon Counting detector (Dectris), then
integrated and scaled using DIALS,22 via the XIA2 expert system,23 and
merged using AIMLESS;24 the resulting data-collection statistics are sum-
marized in Table 2. The M. smegmatis GyrB22-novobiocin complex structure
was solved by molecular replacement with PHASER,25 using chain A from
the published M. smegmatis structure (PDB code 4B6C)21 as a template.
This was then used as a template to solve the M. thermoresistibile GyrB21-
novobiocin complex structure, where the sequence identity between these
ATPase domains is 80%. The molecular replacement models were rebuilt
using BUCCANEER26 before being completed through iterative rounds of re-
finement (REFMAC27) and manual model building (COOT28). The initial
model of the M. thermoresistibile GyrB21–Redx03863 complex structure
was subsequently obtained by direct refinement of the protein component
of the GyrB21–novobiocin complex, then completed as above. Structures
were validated through MOLPROBITY29, PDB-REDO30 and the PDB-
validation server.31 The refinement and validation statistics are summar-
ized in Table 2. Omit mFobs#DFcalc difference electron density for bound
ligands was calculated using phases from the final models without the lig-
and after the application of small random shifts to the atomic coordinates,
re-setting temperature factors and re-refining to convergence. All struc-
tural figures were prepared using CCP4mg.32
Enzymes and assays
DNA gyrase from M. tuberculosis was purified as previously described.33
Supercoiling assays were carried out as described;33 ATPase assays were
performed using the PK/LDH-linked assay.34 Gyrase from M. thermoresistibile
was cloned and purified using methods analogous to those used for
M. tuberculosis (see Supplementary data).
Results and discussion
Antibacterial activity
We initially tested the two compounds (Redx03863 and
Redx04739) of interest against selected bacterial strains, including
E. coli and M. smegmatis, to determine if they were selective for
mycobacteria (Table 1). We found that Redx04739 showed a sig-
nificantly lower MIC against M. smegmatis compared with the
other species tested. Redx03863 was more potent and showed
good activity against all five strains.
Inhibition of DNA gyrase
Redx03863 and Redx04739 compounds were confirmed to inhibit
DNA gyrase from M. tuberculosis (Figure 2) using a gel-based super-
coiling assay; the IC50s for M. tuberculosis gyrase were determined
to be 9.0 nM (Redx03863) and 30 nM (Redx04739). Gyrase can also
relax supercoiled DNA in the absence of ATP;35 we found that the
Redx compounds did not inhibit this reaction. In the presence of
FQs, gyrase can cleave DNA due to the cleavage complex being
stabilized.35 We found that these compounds did not stabilize the
cleavage complex (Figure S1). Therefore, we suggest that, consist-
ent with other similar compounds, Redx03863 and Redx04739
could be ATPase inhibitors.15,17,18
We directly tested Redx03863 and Redx04739 in gyrase
ATPase reactions and found that both compounds inhibit the
ATPase reaction of M. tuberculosis gyrase with high efficiency, like
that of novobiocin (Figure 3), with IC50 values of 200 nM. As the
gyrase concentration used in the ATPase assays was 200 nM it is
not feasible to determine IC50 values that are lower than this.
These data suggest that the binding of Redx03863 and
Redx04739 results in reduced ATPase activity, and that their bind-
ing site may be close to the ATP-binding site within GyrB.
Bacterial mutagenesis
Using a plate-based assay at 4% agar MIC of Redx03863, an
M. smegmatis strain was isolated that was found to have a resist-
ance mutation in the GyrB ATPase region (Gly83Ser; Table S2),
which has been previously implicated in resistance to novobio-
cin.36,37 This mutant strain showed a 16-fold increase in resistance
to the parent compound (Redx03863), alongside an 8-fold
Table 1. MIC values of Redx03863 and Redx04739 for selected bacterial
strains
Bacterial strain
MIC (mg/L)
Redx03863 Redx04739
A. baumannii NCTC 13420 0.031 64
E. coli ATCC 25922 0.016 8
M. smegmatis ATCC 19420 0.016 0.25
P. aeruginosa ATCC 27853 4 32
S. aureus ATCC 29213 0.125 8
Novel GyrB antibiotics JAC
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Table 2. Summary of X-ray data and model parameters for GyrB N-terminal sub-domains
Protein
GyrB21 GyrB21 GyrB24
Organism M. thermoresistibile M. thermoresistibile M. smegmatis
Drug novobiocin Redx03863 novobiocin
Data collection
Diamond Light Source
beamline
I03 I03 I04-1
wavelength (A˚) 0.9700 0.9700 0.9159
detector Pilatus 6M Pilatus 6M Pilatus 6M
resolution range (A˚) 81.86–1.40 (1.42–1.40) 51.67–1.50 (1.53–1.50) 78.48–1.60 (1.63–1.60)
space group P21 P21 C2
cell parameters (A˚/) a = 43.96, b = 51.11,
c = 83.21, b= 100.33
a = 43.77, b = 51.67,
c = 82.91, b= 100.25
a = 156.96, b = 56.11,
c = 50.69, b= 90.66
total no. of measured
intensities
463106 (21837) 374604 (18170) 387422 (19275)
unique reflections 71663 (3548) 58503 (2863) 58273 (2853)
multiplicity 6.5 (6.2) 6.4 (6.3) 6.6 (6.8)
mean I/r(I) 15.7 (1.7) 12.5 (1.2) 10.4 (2.0)
completeness (%) 100.0 (100.0) 100.0 (99.9) 100.0 (100.0)
Rmerge
a 0.048 (0.875) 0.062 (1.455) 0.110 (1.071)
Rmeas
b 0.052 (0.956) 0.067 (1.588) 0.119 (1.159)
CC1=2
c 0.999 (0.849) 0.999 (0.679) 0.999 (0.647)
Wilson B value (A˚2) 16.87 20.3 15.73
Refinement
resolution range (A˚) 81.86–1.40 (1.44–1.40) 43.69–1.50 (1.54–1.50) 78.48–1.60 (1.64–1.60)
reflections: working/freed 67991/3649 (4988/280) 55659/2826 (4079/208) 55300/2973 (4085/214)
Rwork/Rfree
e 0.140/0.181 (0.240/0.257) 0.149/0.203 (0.278/0.320) 0.137/0.188 (0.260/0.310)
Ramachandran plot:
favoured/allowed/
disallowedf (%)
97.42/2.58/0.00 96.82/3.18/0.00 98.07/1.93/0.00
RMSD, bond distance (A˚) 0.009 0.011 0.011
RMSD, bond angle () 1.513 1.659 1.514
No. of protein residues (ranges) A: 20–102, 123–213, 245–254 A: 20–102, 123–213, 245–253 A: 16–102, 123–213, 246–255
B: 22–88, 92–102,
123–213, 245–254
B: 22–87, 92–102,
123–213, 245–253
B: 18–102, 123–213, 246–255
no. of water/drug/zinc/
Na/EDO/act/PEG molecules
296/2/6/2/0/0/0 291/2/6/2/0/0/0 379/2/0/5/10/3
mean B factors: protein/
ions/ligands/waters (A˚2)
23.4/25.5/26.8/37.8 26.7/31.5/26.5/38.0 22.5/29.0/26.7/35.0
RSCC scores for main ligandg A: 0.96; B: 0.94
(for both conformers)
A: 0.94; B: 0.94 A: 0.96; B: 0.97
PDB accession code 6Y8L 6Y8N 6Y8O
Values in parentheses are for the outer resolution shell.
aRmerge =
P
hkl
P
i jIi(hkl)# hI(hkl)ij/
P
hkl
P
iIi(hkl).
bRmeas =
P
hkl [N/(N#1)]
1/2%
P
i jIi(hkl)# hI(hkl)ij/
P
hkl
P
iIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, hI(hkl)i is the weighted average in-
tensity for all observations i of reflection hkl and N is the number of observations of reflection hkl.
cCC1=2 is the correlation coefficient between symmetry equivalent intensities from random halves of the dataset.
dThe dataset was split into ‘working’ and ‘free’ sets consisting of 95% and 5% of the data, respectively. The free set was not used for refinement.
eThe R-factors Rwork and Rfree are calculated as follows: R =
P
(j Fobs# Fcalc j)/
Pj Fobs j, where Fobs and Fcalc are the observed and calculated structure
factor amplitudes, respectively.
fAs calculated using MolProbity.
gReal space correlation coefficients from PDB validation server.
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increase in resistance to Redx04739 and a 32-fold increase in re-
sistance to novobiocin. This cross-resistance suggests that the
three compounds bind at a similar site in GyrB.
Structure of Redx03863-binding pocket
Redx03863 and Redx04739 impact DNA gyrase activities, suggest-
ing that they are likely to bind at the ATP-binding site of myco-
bacterial GyrB. Attempts to co-crystallize the Redx compounds
with the GyrB ATPase sub-domain from M. tuberculosis and
M. smegmatis were not successful, although we were able to
obtain crystals of the M. smegmatis protein with novobiocin and
solve the structure to 1.6 A˚ resolution (Figure S2; note that novo-
biocin has previously been shown to bind to M. smegmatis GyrB38).
We have investigated gyrase from M. thermoresistibile and found it
to be more stable than the M. tuberculosis enzyme (Figure S3).
Based on these findings, we successfully co-crystallized a 21 kDa
N-terminal sub-domain of M. thermoresistibile GyrB (residues
20–254 with residues 103–122 and 214–244 excluded) with novo-
biocin and Redx03863. This N-terminal sub-domain had been pre-
viously used to determine the novobiocin-binding site in gyrase
from other organisms.39–41 This fragment readily crystallized in
the presence of novobiocin, giving diffraction to 1.4 A˚, and the
structure was solved by molecular replacement (Figure 4), using
the structure of the equivalent fragment from M. smegmatis with
bound novobiocin described above. Superposition of the two
mycobacterial novobiocin complexes gave a root mean square de-
viation (RMSD) value of 0.688 A˚, indicating that they are closely
similar. Using cross-seeding from crystals of the novobiocin com-
plex, crystals of Redx03863 bound to the 21 kDa fragment were
obtained, which diffracted to a resolution of 1.5 A˚. The structure
was solved using molecular replacement from the novobiocin
complex structure (Figure 4). This new crystal structure demon-
strated that the binding mode of Redx03863 partially overlaps
those of novobiocin and 50-adenylyl-b,c-imidodiphosphate
(ADPNP; Figures 4 and S4). However, in contrast to novobiocin,
Redx03863, is more deeply buried and shows a greater corres-
pondence in atomic positions to ADPNP, most notably in the over-
lap of the pyrrolopyrimidine and adenine rings (Figure S4).
Residue Arg141 (Arg136 in E. coli) makes a key contact to the
aminocoumarin ring system of novobiocin;39–41 the direct inter-
action between Arg141 and the aminocoumarin ring system of
novobiocin has been crystallographically confirmed, and mutation
at this residue leads to resistance to the drug.39,42–44 In the
Redx03863 complex, there is only a water-mediated interaction
between Arg141 and the ligand (Figure 3). Indeed, when we made
site-directed mutations to Ala and Gln at Arg141 in M. tuberculosis
GyrB, the mutated proteins showed only weak supercoiling activity
and were susceptible to inhibition by Redx03863 (Figure S5),
i.e. this water-mediated contact does not greatly affect the
Figure 2. Inhibition of M. tuberculosis gyrase supercoiling by Redx03863
and Redx04739. Supercoiling assays using 74 nM of each gyrase subunit
in the presence of a range of concentrations of the compounds: (a)
Redx03863 and (b) Redx04739 (1 nM–1000 nM in 1% DMSO). Controls:
#ve (no enzyme), !ve [gyrase (A2B2) only, no compound], DMSO (en-
zyme in 1% DMSO), Novo (10lM novobiocin in 1% DMSO). Apparent IC50
values were determined to be 9 nM for Redx03863 and 30 nM for
Redx04739. Enzyme concentration was chosen to give less than 100%
supercoiling for better determination of the IC50 values.
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Figure 3. Inhibition of gyrase ATPase activity. Plots of the M. tuberculosis gyrase ATPase activity in the presence of Redx03863, Redx04739 and novo-
biocin. All data are shown as the number of ATP molecules turned over per second by each individual GyrB subunit against the log of the inhibitor con-
centration. Assays were carried out using the M. tuberculosis GyrBA fusion protein (Supplementary data) at 200 nM, in the presence of linear pBR322
DNA (20 lg/mL). IC50s were determined to be 0.21lM (novobiocin), 0.17lM (Redx03863) and 0.21lM (Redx04739); note that these are apparent
IC50s due to the high concentration of enzyme. Error bars represent the range of individual replicates, with a minimum of two repeats.
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Figure 4. Structures of M. thermoresistibile GyrB N-terminal sub-domain complexed with novobiocin and Redx03896. (a) Overview of M. tuberculosis
GyrB47 homodimer structure (PDB code 3ZKB) in ribbon representation with ADPNP bound (van der Waals spheres). The equivalent of the
M. thermoresistibile GyrB N-terminal 21 kDa sub-domain is coloured cream with the rest of the subunit in gold. The open red arrow indicates the direc-
tion of view for parts (b) to (f). (b) Close-up of the M. tuberculosis GyrB ATP-binding site with ADPNP bound in stick representation (green carbons). Also
shown in sticks (gold carbons) are the equivalents of residues that were mutated in M. thermoresistibile GyrB21 in this study. (c) Two-dimensional
schematic showing direct hydrogen bonds and those mediated by a single water molecule between novobiocin and M. thermoresistibile GyrB21;
van der Waals interactions are indicated by grey arcs. (d) Equivalent of part (c) showing the actual structure with 1.4 A˚ resolution omit mFobs#DFcalc
difference electron density contoured at 3.0 r and the protein backbone traced as a semi-transparent ribbon. Only residues that interact with the
ligand (sticks; green carbons), via hydrogen bonds or van der Waals contacts, are included (sticks; yellow carbons). (e) and (f) Representations corre-
sponding to panels (c) and (d), respectively, but for the complex with Redx03896, where the omit mFobs#DFcalc difference electron density is at 1.6 A˚
resolution and contoured at 3.0 r.
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interaction of Redx03863 with gyrase. When we selected for spon-
taneous resistance mutations to Redx03863 in M. smegmatis, the
only mutation that we could isolate was Gly83Ser; no mutations at
Arg141 were found, again suggesting it is of minor importance. In
relation to Gly83 to Ser, the presence of a side chain at this position
would cause steric clashes with the neighbouring structure
and most likely displace and/or destabilize the loop bearing residue
83, which also contains several other important ligand-binding
residues, namely Arg82, Ile84 and Pro85 (Figure 4e and f).
M. tuberculosis GyrB containing this mutation (Gly83Ser) showed
no activity in vitro. The effect on ATP binding is less obvious from
the M. tuberculosis GyrB47 dimer structure (N-terminal ATPase do-
main of GyrB),45 although it could affect dimer formation and
thereby compromise activity. Additionally, based on the crystal
structure (Figure 4), we made mutations at Asn52, Glu56, Asp79
and Arg82 (all to Ala) in M. tuberculosis GyrB; three of these
mutations, or their equivalents, have been found previously to af-
fect ATPase activity.36,37,39,46 We found that none of these mutant
enzymes showed any supercoiling activity (Figure S6). This sug-
gests that selecting resistance mutations to Redx03863 is difficult
without compromising enzyme activity, which is a feature in
favour of exploiting these compounds as leads for antimicrobial
chemotherapy.
In summary, we have determined the mode of action for
Redx03863 and Redx04739, including our proposal for the binding
site of Redx03863, as elucidated by X-ray crystallography.
Therefore, we conclude that, like other tricyclic pyrrolopyrimidine
compounds,15,17 Redx03863 and Redx04739 bind tightly to GyrB
within a pocket overlapping with parts of the binding pockets of
both novobiocin and ATP, thus preventing ATP turnover and DNA
supercoiling from occurring. A large number of compounds that
bind at or near the ATP-binding pocket of GyrB have been devel-
oped in recent years.13,14,47,48 This is largely due to the fact that
the crystal structure of the N-terminal sub-domain of E. coli GyrB
bound to novobiocin has been known since 1996,41 enabling the
use of computational design and chemical synthesis. Although
novobiocin has been used as a clinical antibiotic, it is not currently
used. At the time of writing no other GyrB inhibitors that bind to
this region are in common clinical use as antibiotics. This is likely
due to issues connected with solubility and ease of penetration
into bacteria. The fact that GyrB proteins containing mutations in
the Redx03863-binding site were largely inactive is potentially a
positive feature of these compounds. Taken together with the rela-
tively small size of Redx03863 and Redx04739, their ease of syn-
thesis, and their activity against Gram-negative and Gram-positive
bacteria, including M. tuberculosis, this suggests that these
compounds could have future promise to be further exploited as
potential antibiotics.
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